Harvard Catalyst Profiles
Contact, publication, and social network information about Harvard faculty and fellows.
Home
About
Overview
Open Source Software
Help
History (1)
Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats.
See All Pages
Find People
Find Everything
Login
to
edit your profile
(add a photo, education, awards, etc.), search
student opportunities
, and
create reports
.
Edit My Profile
My Person List (
0
)
Opportunity Search
Return to Top
Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats.
Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats. J Hepatol. 2009 Nov; 51(5):865-73.
View in:
PubMed
subject areas
Angiogenesis Inhibitors
Animals
Benzenesulfonates
Cell Proliferation
Cytokines
Down-Regulation
Hemodynamics
Hypertension, Portal
Ligation
Male
Neovascularization, Pathologic
Niacinamide
Nitric Oxide Synthase Type III
Phenylurea Compounds
Portal Vein
Protein Kinase Inhibitors
Pyridines
Rats
Rats, Sprague-Dawley
RNA, Messenger
Splanchnic Circulation
authors with profiles
Philipp Schwabl, Ph.D.